Endometriosis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Endometriosis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Mitsubishi Tanabe Pharma America, Ferring Pharmaceuticals, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Organon

[Nevada, United States] - DelveInsight's "Endometriosis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Endometriosis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Endometriosis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Endometriosis Market Report:
The Endometriosis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In September, 2024: AbbVie announced that their study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endometriosis and associated pain.
In September, 2024: Hope Medicine (Nanjing) Co., Ltd announced that their study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
In August, 2024: Bio Meds Pharmaceutica Ltda announced that their studies aims to evaluate the effects of therapy with implantable Gestrinone compared to oral Dienogest in relieving complaints related to endometriosis.
In August, 2024: Organon and Co announced that the purpose of their study was to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
In July, 2024: Mitsubishi Tanabe Pharma America Inc. announced that the purpose of their study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis.
In 2023, the diagnosed prevalent cases of endometriosis in the US were ~4,800,000 cases, which might increase by 2034.
In 2023, It has been observed that in the US, the highest number of endometriosis-affected people were found in the 18─29 years of age group with ~5,000,000 cases.
In 2023, the diagnosed prevalent cases of endometriosis by pain severity in the US were ~1,200,000 for mild, ~1,900,000 for moderate, and ~1,600,000 for severe, which are expected to rise during our forecast period (2024-2034)
Key Endometriosis Companies are as follows: Mitsubishi Tanabe Pharma America, Ferring Pharmaceuticals, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Organon
Key Endometriosis Therapies are as follow: Implantable gestrinone, SN132D, OG-6219, Elagolix, Relugolix, Estradiol/norethindrone acetate, HMI-115, Quinagolide, OBE2109, Elagolix, SHR7280, linzagolix, TAK-385, NBI-56418
Launching multiple stage Endometriosis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Endometriosis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Endometriosis Overview:
Endometriosis is a chronic inflammatory disease that requires lifelong management. Three main therapeutic options exist for endometriosis management: medical treatment, surgery, and ART.

Endometriosis Epidemiology Segmentation:
The Endometriosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Endometriosis Total Prevalent Cases
Endometriosis Diagnosed Prevalent Cases
Endometriosis Age-specific Diagnosed Prevalent Cases
Endometriosis Treated Cases

For more information about Endometriosis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Endometriosis Market Insights
The endometriosis market is evolving, with increased focus on developing new therapies and improving diagnosis and management strategies. Recent years have seen a surge in research and product development aimed at addressing this condition.

Endometriosis Drugs Uptake
ORILISSA (elagolix) developed by AbbVie was the first FDA-approved oral treatment for managing moderate-to-severe pain associated with endometriosis.
MYFEMBREE/RYEQO (relugolix, estradiol, and norethindrone acetate) developed by Myovant is an oral once-daily tablet indicated for the treatment of pain associated with endometriosis.
RELUMINA (relugolix) manufactured by ASKA Pharmaceuticals is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Endometriosis Therapies and Key Companies:
Implantable gestrinone: Bio Meds Pharmaceutica Ltda
SN132D: Spago Nanomedical AB
OG-6219: Organon and Co
Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical
Elagolix: Qilu Pharmaceutical (Hainan) Co., Ltd.
Relugolix, Estradiol/norethindrone acetate: Myovant Sciences GmbH
HMI-115: Hope Medicine (Nanjing) Co., Ltd
Quinagolide: Ferring Pharmaceuticals
OBE2109: ObsEva SA
Elagolix: AbbVie
SHR7280: Jiangsu HengRui Medicine Co., Ltd.
linzagolix: Kissei Pharmaceutical Co., Ltd.
TAK-385: ASKA Pharmaceutical Co., Ltd.
NBI-56418: Abbott

Endometriosis Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Endometriosis.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Endometriosis Market Drivers:
Increased Awareness and Diagnosis
Research and Development
Unmet Medical Needs
Patient-Centric Care

Endometriosis Market Barriers:
High Cost of Treatment:
Limited Understanding of Disease Mechanisms
Side Effects and Treatment Discontinuation

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Endometriosis Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Endometriosis Companies: Mitsubishi Tanabe Pharma America, Ferring Pharmaceuticals, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Organon
Key Endometriosis Therapies: Implantable gestrinone, SN132D, OG-6219, Elagolix, Relugolix, Estradiol/norethindrone acetate, HMI-115, Quinagolide, OBE2109, Elagolix, SHR7280, linzagolix, TAK-385, NBI-56418
Endometriosis Therapeutic Assessment: Current marketed and emerging therapies
Endometriosis Market Dynamics: Endometriosis Market drivers and Endometriosis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Endometriosis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Endometriosis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Endometriosis Market Overview at a Glance
4 Executive Summary of Endometriosis
5 Key Events
6 Epidemiology and Market Methodology
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Therapies
11 Emerging Therapies
12 Endometriosis: 7 Major Market Analysis
13 Market Access and Reimbursement
14 SWOT Analysis
15 Unmet needs
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.